Drug: KALETRA Injury: Foetal exposure during pregnancy Quarter: 2016Q3
Total Records: 27 Number of Pages: 2
Event ID | DRUGNAME | PT | Drug Manufacturer | Patient Age | Sex | Weight | Date (YYYYMMDD) | Country |
---|---|---|---|---|---|---|---|---|
127641321 | KALETRA | Foetal exposure during pregnancy | ABBVIE | 0.00 DY | F | 3 KG | 20160920 | JP |
127710691 | KALETRA | Foetal exposure during pregnancy | ABBVIE | 0.00 | F | 2 KG | 20160922 | JP |
127725802 | KALETRA | Foetal exposure during pregnancy | ABBVIE | 0.00 | M | 0 | 20160928 | JP |
127756571 | KALETRA | Foetal exposure during pregnancy | ABBVIE | 0.00 | F | 2 KG | 20160923 | JP |
127763051 | KALETRA | Foetal exposure during pregnancy | ABBVIE | 0.00 | M | 2 KG | 20160923 | JP |
127903441 | KALETRA | Foetal exposure during pregnancy | ABBVIE | 0.00 | M | 0 | 20160928 | COUNTRY NOT SPECIFIED |
643121811 | KALETRA | Foetal exposure during pregnancy | BRISTOL MYERS SQUIBB | 0.00 | F | 3 KG | 20160902 | ZA |
Total Records: 27 Number of Pages: 2